• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Stivarga (regorafenib)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Stivarga (regorafenib)

  • Profile

Profile

Contact Information

Contact: Bayer
Website: https://www.stivarga-us.com/

Currently Enrolling Trials

    Show More

    Stivarga (regorafenib) - 3 indications

    • the treatment of metastatic colorectal cancer; approved September 2012
    • the treatment of gastrointestinal stromal tumor; approved February 2013
    • the treatment of hepatocellular carcinoma; approved April 2017

    General Information

    Stivarga (regorafenib) is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.

    Stivarga is specifically indicated for the following conditions:

    • the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy
    • for patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor who have been previously treated with imatinib mesylate and sunitinib malate
    • for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib

    Stivarga is supplied as tablets for oral administration. The recommended dose is 160 mg Stivarga (four 40 mg tablets) taken orally once daily for the first 21 days of each 28-day cycle. Continue treatment until disease progression or unacceptable toxicity.

    Take Stivarga at the same time each day. Swallow tablet whole with water after a low-fat meal that contains less than 600 calories and less than 30% fat. Do not take two doses of Stivarga on the same day to make up for a missed dose from the previous day.

    Mechanism of Action

    Stivarga (regorafenib) is a potent oral multi-kinase inhibitor with a kinase inhibition profile targeting angiogenic, stromal and oncogenic receptor tyrosine kinases (TK). This distinct anti-angiogenic profile includes inhibition of both VEGFR2 and TIE2 TK.

    Side Effects

    Adverse effects associated with the use of Stivarga may include, but are not limited to, the following:

    • asthenia/fatigue
    • decreased appetite and food intake
    • hand-foot skin reaction (palmar-plantar erythrodysesthesia)
    • diarrhea
    • mucositis
    • weight loss
    • infection
    • hypertension
    • dysphonia

    The Stivarga drug label comes with the following Black Box Warning: HEPATOTOXICITY Severe and sometimes fatal hepatotoxicity has occurred in clinical trials. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue Stivarga for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence.

    Indication 1 - metastatic colorectal cancer

    approved September 2012

    Clinical Trial Results

    The FDA approval of Stivarga for colorectal cancer was based in part on an international, multi-center, randomized, double-blind, placebo-controlled trial in 760 subjects with previously treated metastatic colorectal cancer. The subjects received 160 mg Stivarga orally once daily plus Best Supportive Care (BSC) or placebo plus BSC for the first 21 days of each 28-day cycle. Stivarga was administered with a low-fat breakfast (less than 30% fat). The primary efficacy endpoint was overall survival (OS). The secondary endpoints included progression-free survival (PFS) and objective tumor response rate. The median overall survival was 6.4 months for the Stivarga arm versus 5.0 months for the placebo arm (p=0.0102). The median PFS was 2.0 months versus 1.7 months and the overall tumor response rate was 5 (1%) versus 1 (0.4%) for the Stivarga arm versus the placebo arm, respectively.

    Indication 2 - gastrointestinal stromal tumor

    approved February 2013

    Clinical Trial Results

    The FDA approval of Stivarga for GIST was based on an international, multi-center, randomized (2:1), double-blind, placebo-controlled trial in 199 subjects with unresectable, locally advanced or metastatic gastrointestinal stromal tumor (GIST), who had been previously treated with imatinib mesylate and sunitinib malate. The subjects received 160 mg regorafenib orally once daily plus best supportive care (BSC) or placebo plus BSC for the first 21 days of each 28-day cycle. Treatment continued until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) based on disease assessment by independent radiological review using modified RECIST 1.1 criteria. The percentage of subjects with death or progression was 62% in the Stivarga arm versus 96% in the placebo arm. The median PFS was 4.8 months versus 0.9 months for the Stivarga and placebo arms, respectively.

    Indication 3 - hepatocellular carcinoma

    approved April 2017

    Clinical Trial Results

    The FDA approval of Stivarga for the treatment of HCC was based on a randomized trial of 573 patients with HCC whose tumors had progressed after receiving sorafenib. The trial measured the length of time the patients lived after receiving treatment (overall survival), the length of time tumors did not grow after treatment (progression-free survival) and the percent of patients whose tumors completely or partially shrank after treatment (overall response rate). The median overall survival for patients taking Stivarga was 10.6 months, compared to 7.8 months for patients taking a placebo. The median progression-free survival for patients taking Stivarga was 3.1 months compared to 1.5 months for patients taking a placebo. The overall response rate for patients taking Stivarga was 11 percent, compared to 4 percent of patients taking placebo.

    Approval Date: 2012-09-01
    Company Name: Bayer
    Back to Listings

    Upcoming Events

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing